These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34893967)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.
    Piechowski-Jozwiak B; Abidi E; El Nekidy WS; Bogousslavsky J
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):165-176. PubMed ID: 34893967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmoteplase.
    Paciaroni M; Medeiros E; Bogousslavsky J
    Expert Opin Biol Ther; 2009 Jun; 9(6):773-8. PubMed ID: 19456211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
    von Kummer R; Mori E; Truelsen T; Jensen JS; Grønning BA; Fiebach JB; Lovblad KO; Pedraza S; Romero JM; Chabriat H; Chang KC; Dávalos A; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A; Albers GW;
    Stroke; 2016 Dec; 47(12):2880-2887. PubMed ID: 27803391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
    Mori E; Minematsu K; Nakagawara J; Hasegawa Y; Nagahiro S; Okada Y; Truelsen T; Lindsten A; Ogawa A; Yamaguchi T;
    Stroke; 2015 Sep; 46(9):2549-54. PubMed ID: 26251244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
    Fiebach JB; Al-Rawi Y; Wintermark M; Furlan AJ; Rowley HA; Lindstén A; Smyej J; Eng P; Warach S; Pedraza S
    Stroke; 2012 Jun; 43(6):1561-6. PubMed ID: 22474060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program.
    von Kummer R; Albers GW; Mori E;
    Int J Stroke; 2012 Oct; 7(7):589-96. PubMed ID: 22989394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of desmoteplase-induced fibrinolytic activity in vitro.
    Hoffmann JJ; Kops O
    J Thromb Thrombolysis; 2005 Aug; 20(1):23-6. PubMed ID: 16133891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
    Hacke W; Furlan AJ; Al-Rawi Y; Davalos A; Fiebach JB; Gruber F; Kaste M; Lipka LJ; Pedraza S; Ringleb PA; Rowley HA; Schneider D; Schwamm LH; Leal JS; Söhngen M; Teal PA; Wilhelm-Ogunbiyi K; Wintermark M; Warach S
    Lancet Neurol; 2009 Feb; 8(2):141-50. PubMed ID: 19097942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmoteplase as a potential treatment for cerebral ischaemia.
    Patel R; Ispoglou S; Apostolakis S
    Expert Opin Investig Drugs; 2014 Jun; 23(6):865-73. PubMed ID: 24766516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects.
    López-Atalaya JP; Roussel BD; Ali C; Maubert E; Petersen KU; Berezowski V; Cecchelli R; Orset C; Vivien D
    Stroke; 2007 Mar; 38(3):1036-43. PubMed ID: 17325305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
    Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
    Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.
    Freeman R; Niego B; Croucher DR; Pedersen LO; Medcalf RL
    Brain Res; 2014 May; 1565():63-73. PubMed ID: 24675027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmoteplase in acute massive pulmonary thromboembolism.
    Tebbe U; Bramlage P; Graf A; Lechleitner P; Bode C; Riess FC; Clemens N; Al-Rawi Y; Konstantinides S; Goldhaber SZ
    Thromb Haemost; 2009 Mar; 101(3):557-62. PubMed ID: 19277420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
    Li X; Ling L; Li C; Ma Q
    Medicine (Baltimore); 2017 May; 96(18):e6667. PubMed ID: 28471961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials.
    Warach S; Al-Rawi Y; Furlan AJ; Fiebach JB; Wintermark M; Lindstén A; Smyej J; Bharucha DB; Pedraza S; Rowley HA
    Stroke; 2012 Sep; 43(9):2313-8. PubMed ID: 22738918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: desmoteplase, PAION/Forest.
    Debens T
    Curr Opin Mol Ther; 2004 Oct; 6(5):567-75. PubMed ID: 15537059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
    Paris C; Derex L
    Rev Neurol (Paris); 2015 Dec; 171(12):866-75. PubMed ID: 26563662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.
    Liberatore GT; Samson A; Bladin C; Schleuning WD; Medcalf RL
    Stroke; 2003 Feb; 34(2):537-43. PubMed ID: 12574572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.